Works by Lavie, D.

Results: 12
    1
    2

    P1087: FAVEZELIMAB (ANTI–LAG‐3) AND PEMBROLIZUMAB CO‐BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD‐1 THERAPY: AN OPEN‐LABEL PHASE 1/2 STUDY.

    Published in:
    HemaSphere, 2022, v. 6, p. 977, doi. 10.1097/01.HS9.0000847216.85071.f3
    By:
    • Herrera, A. F.;
    • Lavie, D.;
    • Johnson, N. A.;
    • Avigdor, A.;
    • Borchmann, P.;
    • Andreadis, C.;
    • Bazargan, A.;
    • Gregory, G.;
    • Keane, C.;
    • Inna, T.;
    • Vucinic, V.;
    • Zinzani, P. L.;
    • Zhang, H.;
    • Pillai, P.;
    • Marinello, P.;
    • Timmerman, J.
    Publication type:
    Article
    3

    P1086: FAVEZELIMAB (ANTI–LAG‐3) AND PEMBROLIZUMAB CO‐BLOCKADE IN ANTI–PD‐1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN‐LABEL PHASE 1/2 STUDY.

    Published in:
    HemaSphere, 2022, v. 6, p. 976, doi. 10.1097/01.HS9.0000847212.00073.29
    By:
    • Gregory, G.;
    • Timmerman, J.;
    • Lavie, D.;
    • Borchmann, P.;
    • Herrera, A. F.;
    • Minuk, L.;
    • Vucinic, V.;
    • Armand, P.;
    • Avigdor, A.;
    • Gasiorowski, R.;
    • Herishanu, Y.;
    • Keane, C.;
    • Kuruvilla, J.;
    • Palcza, J.;
    • Pillai, P.;
    • Marinello, P.;
    • Johnson, N. A.
    Publication type:
    Article
    4

    P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM].

    Published in:
    HemaSphere, 2022, v. 6, p. 940, doi. 10.1097/01.HS9.0000847068.32650.9b
    By:
    • Vannucchi, A.;
    • Mesa, R.;
    • Gerds, A.;
    • Al‐Ali, H. K.;
    • Lavie, D.;
    • Kuykendall, A.;
    • Grosicki, S.;
    • Iurlo, A.;
    • Goh, Y. T.;
    • Lazaroiu, M.;
    • Egyed, M.;
    • Fox, M. L.;
    • McLornan, D.;
    • Perkins, A.;
    • Yoon, S.‐S.;
    • Gupta, V.;
    • Kiladjian, J.‐J.;
    • Donahue, R.;
    • Kawashima, J.;
    • Verstovsek, S.
    Publication type:
    Article
    5

    S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR.

    Published in:
    HemaSphere, 2022, v. 6, p. 96, doi. 10.1097/01.HS9.0000843672.56808.41
    By:
    • Verstovsek, S.;
    • Vannucchi, A.;
    • Gerds, A.;
    • Al‐Ali, H. K.;
    • Lavie, D.;
    • Kuykendall, A.;
    • Grosicki, S.;
    • Iurlo, A.;
    • Goh, Y. T.;
    • Lazaroiu, M.;
    • Egyed, M.;
    • Fox, M. L.;
    • McLornan, D.;
    • Perkins, A.;
    • Yoon, S.‐S.;
    • Gupta, V.;
    • Kiladjian, J.‐J.;
    • Donahue, R.;
    • Kawashima, J.;
    • Mesa, R.
    Publication type:
    Article
    6

    An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 364, doi. 10.1002/hon.3164_263
    By:
    • Lavie, D.;
    • Johnson, N.;
    • Borchmann, P.;
    • Herrera, A. F.;
    • Avigdor, A.;
    • Gasiorowski, R.;
    • Gregory, G.;
    • Keane, C.;
    • Vucinic, V.;
    • Bazargan, M.;
    • Herishanu, Y.;
    • Minuk, L.;
    • Tzoran, I.;
    • Andreadis, C.;
    • Armand, P.;
    • Kuruvilla, J.;
    • Zinzani, P. L.;
    • West, R. Marceau;
    • Pillai, P.;
    • Marinello, P.
    Publication type:
    Article
    7
    8
    9
    10
    11
    12